vasamed Announces Unetixs Vascular as U.S. Distribution Partner for SensiLase(TM) Microvascular Assessment System Long-Time Supplier to Vascular Labs Adds Diabetic Foot Ulcer Diagnostic MINNEAPOLIS, July 12 /PRNewswire-FirstCall/ -- vasamed (OTC:OPTL) (BULLETIN BOARD: OPTL) , a leader in non-invasive, hemodynamic assessment technology, and Unetixs Vascular Inc. announced that they have entered into a contractual agreement under which Unetixs Vascular will provide U.S. distribution for vasamed's SensiLase(TM) Microvascular Assessment System, a non-invasive monitoring system that is used to assess diabetic foot ulcers. "We are extremely pleased to have Unetixs Vascular and their full-service, nationwide team join us in the distribution of SensiLase to the vascular marketplace. The team at Unetixs Vascular sells the most complete and technically advanced line of instrumentation for diagnostic vascular testing," said Terry Duesterhoeft, vice president Sales & Marketing of vasamed. "Unetixs Vascular has a solid reputation as a provider of testing equipment for early detection of peripheral arterial disease (PAD), a build-up of plaque through the arteries, which can ultimately lead to strokes and heart attacks. They are leaders in the vascular community and have the ability to expand our reach to customers who are seeking to provide a full-range of diagnostic services to their patients." "Our strategic relationship with vasamed positions us to include micro vascular assessment, specifically applied to wound care diagnostics to our state-of-the-art vascular testing product portfolio," said Peter A. Moscovita, President and CEO of Unetixs Vascular. "This partnership allows us to immediately address the growing issue of diabetic foot ulcer disease in the United States, the leading cause of lower limb amputation according to the American Diabetes Association. The inclusion of SensiLase into our sales portfolio also promises to play an important role in expanding our capabilities in PAD and wound care diagnostics." vasamed(TM) designs, licenses, manufactures and distributes products that can be used by your doctor -- right in the office -- to determine if heart and blood vessels are healthy. vasamed's products and technology include SensiLase(TM) Microvascular Assessment System to monitor small blood vessel health, AcQtrac(TM) Impedance Cardiography (ICG) to monitor heart function and Tissue Carbon Dioxide Technologies to monitor tissue wellness. For more information about vasamed technology and services and new products, please call (800) 695.2737 or see the company's web site at http://www.vasamed.com/ . Unetixs Vascular is recognized as a world leading developer of vascular diagnostic testing equipment. Based in Quonset, RI, Unetixs designs and manufactures advanced testing instrumentation that helps provide early detection of peripheral arterial disease (PAD), which can ultimately lead to strokes and heart attacks. For more information about Unetixs Vascular and its products, visit http://www.unetixs.com/ . DATASOURCE: vasamed CONTACT: Wes Peterson, CFO of vasamed, +1-952-944-5857, ext. 542 Web site: http://www.vasamed.com/ http://www.unetixs.com/

Copyright